RxDoctor Payments Data

Roger Middleton

Family · Limerick, PANPI 1821706698

Payments from drug & device makers

$855in general payments, 2019–2025

Across 8 payments — averaging $106.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avadel CNS Pharmaceuticals, LLC$125
  • Dexcom, Inc.$116
  • Boehringer Ingelheim$113
  • Phathom Pharmaceuticals, Inc.$101
  • Amgen$101
  • Mallinckrodt Hospital Products Inc.$100
  • plus $199 from 2 others

What the payments were for

  • Food & beverage$855100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$855 in reported general payments places this provider in the 70th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$41,533
Medicare patients
246
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban27$18,062
MounjaroTirzepatide14$13,984
OzempicSemaglutide13$12,820
Albuterol Sulfate HfaAlbuterol Sulfate58$1,658
Atorvastatin Calcium82$970
Lisinopril67$796
Rosuvastatin Calcium51$769
Fluticasone Propionate43$723
Levothyroxine Sodium54$702
Metoprolol Succinate41$682
Hydroxyzine Hcl13$608
Gabapentin45$501
Omeprazole44$482
Venlafaxine Hcl ErVenlafaxine Hcl23$460
Alprazolam23$445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$99$13,98414 claims
Novo NordiskOzempic$100$12,82013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,717 family providers in Pennsylvania.

Other family in Limerick

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →